Despite negative equity, Amneal raised its operating cash flow guidance for FY25. Read why I agree with Wall St., which is ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Pharma and biotech companies have access to an unprecedented variety of health data, from electronic health records and medical or pharmacy claims to genomic, behavioral and sensor data. | Pharma and ...

Brent Saunders returned to Bausch + Lomb in 2023 to help address unmet needs in eye care, focusing on innovation and ...

BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with ...

Despite economic uncertainty and a steady flow of takeovers and overseas departures, UK equities have staged a strong recovery. AJ Bell investment director ...

Discover how AI, flow chemistry, and NMR come together in the PiPAC project to revolutionize scalable and autonomous API ...

RA Capital Management’s Peter Kolchinsky says the companies that survived the industry’s 2021 rout are thriving—and looking to make deals.

Bayer's pharmaceutical division is navigating what its leader, Stefan Oelrich, calls a "profound transformation" within the industry. He cautions that Europe's competitive edge is eroding, hampered by ...

Discover how drugs prevent, cure, and alleviate ailments. Learn about over-the-counter vs. prescription drugs and the ...

Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced ...